All In Biotech

Drug Trial Radar · NCT03112603

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)

Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

Jun 29, 2017

Primary completion

May 8, 2020

Study completion Dec 15, 2022

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Apr 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

Conditions

  • Graft-versus-host Disease (GVHD)

Interventions

  • RuxolitinibDrug

    Ruxolitinib twice daily at the protocol-defined starting dose.

  • Extracorporeal photopheresis (ECP)Drug

    Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).

  • Low-dose methotrexate (MTX)Drug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Mycophenolate mofetil (MMF)Drug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)Drug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • InfliximabDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • RituximabDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • PentostatinDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • ImatinibDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • IbrutinibDrug

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 VisitTime frame: Cycle 7 Day 1 (each cycle was comprised of 4 weeks)

Locations

191 sites in 31 countries. Site status is shown where the registry gives one.

  • Incyte Investigative Site

    Tucson, Arizona

  • Incyte Investigative Site

    Duarte, California

  • Incyte Investigative Site

    La Jolla, California

  • Incyte Investigative Site

    Los Angeles, California

  • Incyte Investigative Site

    New Haven, Connecticut

  • Incyte Investigative Site

    Wilmington, Delaware

  • Incyte Investigative Site

    Gainesville, Florida

  • Incyte Investigative Site

    Tampa, Florida

  • Incyte Investigative Site

    Chicago, Illinois

  • Incyte Investigative Site

    Chicago, Illinois

  • Incyte Investigative Site

    Chicago, Illinois

  • Incyte Investigative Site

    Maywood, Illinois

  • Incyte Investigative Site

    Indianapolis, Indiana

  • Incyte Investigative Site

    Westwood, Kansas

  • Incyte Investigative Site

    Lexington, Kentucky

  • Incyte Investigative Site

    Boston, Massachusetts

  • Incyte Investigative Site

    Boston, Massachusetts

  • Incyte Investigative Site

    Omaha, Nebraska

  • Incyte Investigative Site

    Hackensack, New Jersey

  • Incyte Investigative Site

    New York, New York

  • Incyte Investigative Site

    New York, New York

  • Incyte Investigative Site

    New York, New York

  • Incyte Investigative Site

    Chapel Hill, North Carolina

  • Incyte Investigative Site

    Durham, North Carolina

  • Incyte Investigative Site

    Winston-Salem, North Carolina

  • Incyte Investigative Site

    Cincinnati, Ohio

  • Incyte Investigative Site

    Cleveland, Ohio

  • Incyte Investigative Site

    Cleveland, Ohio

  • Incyte Investigative Site

    Columbus, Ohio

  • Incyte Investigative Site

    Oklahoma City, Oklahoma

  • Incyte Investigative Site

    Philadelphia, Pennsylvania

  • Incyte Investigative Site

    Pittsburgh, Pennsylvania

  • Incyte Investigative Site

    Pittsburgh, Pennsylvania

  • Incyte Investigative Site

    Nashville, Tennessee

  • Incyte Investigative Site

    Dallas, Texas

  • Incyte Investigative Site

    Houston, Texas

  • Incyte Investigative Site

    Seattle, Washington

  • Incyte Investigative Site

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.